Department of Psychiatry and Neuropsychology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Research School of Mental Health and Neuroscience (Mhens), Maastricht University, Maastricht, the Netherlands.
Mov Disord. 2021 Nov;36(11):2539-2548. doi: 10.1002/mds.28533. Epub 2021 Feb 22.
Anxiety disorders are among the most prevalent and disabling neuropsychiatric syndromes in patients with Parkinson's disease (PD), but no randomized controlled treatment trials of anxiety have been published to date.
The aim of this study was to assess the effectiveness of cognitive behavioral therapy (CBT) in the treatment of anxiety in patients with PD.
Forty-eight patients with PD with anxiety were randomized 1:1 between CBT and clinical monitoring only (CMO). The CBT program was developed to specifically address anxiety symptoms in PD and consisted of 10 weekly sessions. Assessments were conducted by blinded assessors at baseline, at the end of the intervention, after 3 months, and after 6 months (CBT group only). Main outcome measures were the Hamilton Anxiety Rating Scale (HARS) and the Parkinson Anxiety Scale (PAS).
Both the CBT and CMO groups showed clinically relevant improvement. Although there was no between-group difference in outcome on the Hamilton Anxiety Rating Scale (6.7-point reduction in the CBT group versus 3.9-point reduction in the CMO group; P = 0.15), there was both a statistically significant and a clinically relevant between-group difference on the total PAS in favor of CBT (9.9-point reduction in the CBT group versus 5.2-point reduction in the CMO group; P = 0.012), which was due to improvement on the PAS subscales for episodic (situational) anxiety and avoidance behavior. This greater improvement was maintained at 3- and 6-month follow-ups.
CBT is an effective treatment for anxiety in patients with PD and reduces situational and social anxiety, as well as avoidance behavior. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
焦虑障碍是帕金森病(PD)患者中最常见和最致残的神经精神综合征之一,但迄今为止,尚无针对焦虑症的随机对照治疗试验发表。
本研究旨在评估认知行为疗法(CBT)治疗 PD 患者焦虑症的疗效。
48 例 PD 伴焦虑患者按 1:1 随机分为 CBT 组和仅临床监测组(CMO)。CBT 方案是专门针对 PD 中的焦虑症状制定的,包括 10 次每周的治疗。由盲法评估者在基线、干预结束时、3 个月后和 6 个月后(仅 CBT 组)进行评估。主要结局指标为汉密尔顿焦虑量表(HARS)和帕金森焦虑量表(PAS)。
CBT 组和 CMO 组均显示出临床相关的改善。虽然 HARS 评分的组间差异无统计学意义(CBT 组降低 6.7 分,CMO 组降低 3.9 分;P=0.15),但 PAS 总分的组间差异具有统计学意义且有临床意义,CBT 组更优(CBT 组降低 9.9 分,CMO 组降低 5.2 分;P=0.012),这归因于 PAS 子量表中发作性(情境性)焦虑和回避行为的改善。这种更大的改善在 3 个月和 6 个月的随访中得以维持。
CBT 是治疗 PD 患者焦虑症的有效方法,可降低情境性和社交焦虑症以及回避行为。© 2021 作者。运动障碍由 Wiley 期刊公司代表国际帕金森病和运动障碍协会出版。